Huntsman Homes in on the Integration of Precision Medicine in Oncology

Podcast

In our exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.

Welcome to OncLive On Air! I’m your host today, Jessica Hergert.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with David Huntsman, MD, FRCPC, FCCMG, the Dr. Chew Wei Memorial Professor of Gynaecologic Oncology, Canada Research Chair in Molecular and Genomic Pathology, professor in the Departments of Pathology and Laboratory Medicine and Obstetrics and Gynaecology at the University of British Columbia, co-founder and director of OVCARE, and chief medical office of Canexia Health, to discuss the growth of precision medicine across oncology.

In our exclusive interview, Huntsman discussed the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.

Related Videos
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Abdulrahman Sinno, MD
Erin K. Crane, MD, MPH
Núria Agustí Garcia, MD
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Gabriella Smith, MD
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Amin Nassar, MD
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.